Bowel ulceration following tocilizumab administration in a COVID-19 patient
Open Access
- 18 August 2020
- journal article
- research article
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 7 (1), e000484
- https://doi.org/10.1136/bmjgast-2020-000484
Abstract
Tocilizumab, a monoclonal antibody against interleukin-6, has been used to treat cytokine release syndrome (CRS) in a subset of patients with severe COVID-19 disease. Acute ulcerative bowel disease has been only rarely documented in patients treated for rheumatological conditions. The gastrointestinal side effects seen when used in the context of COVID-19 are unknown. We present a case of COVID-19 CRS in which acute terminal ileum and perforated caecal ulceration evolved after tocilizumab exposure. We raise awareness of a possible causal relationship between even a single dose of tocilizumab and gut ulceration in patients with COVID-19. Any such drug enteropathy relationship requires watchful monitoring during upcoming trials of tocilizumab in patients with COVID-19.Keywords
This publication has 32 references indexed in Scilit:
- Evidence for Gastrointestinal Infection of SARS-CoV-2Gastroenterology, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving TocilizumabArchives of Rheumatology, 2018
- Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDsAnnals Of The Rheumatic Diseases, 2016
- IL-6 Stimulates Intestinal Epithelial Proliferation and Repair after InjuryPLOS ONE, 2014
- Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumabRheumatology, 2014
- Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritisEndoscopy, 2010
- Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in miceGut, 2008
- IL-6 Protects enterocytes from hypoxia-induced apoptosis by induction of bcl-2 mRNA and reduction of fas mRNABiochemical and Biophysical Research Communications, 2006
- Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant miceNature Medicine, 2002